# Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia

> **NCT00085891** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 535 (—)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Quetiapine Fumarate

## Key facts

- **NCT ID:** NCT00085891
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** —
- **Final completion:** 2005-09
- **Target enrollment:** 535 (—)
- **Last updated:** 2009-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00085891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00085891, "Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00085891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*